Ticker - MCET (U.S. Reporting: SEC Filer)
Estimated outstanding shares: 4.6 Billion a/o March 2015
Estimated Float: 4.4 Billion a/o March 2015
(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub. For more detailed, up-to-date information on MultiCell Technologies, please go the company website.)
MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:
MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.
|Indication || |
| || || || || |
| || || || || |
| || || || || |
| || || || || |
Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.
MultiCell Technologies, Inc. Corporate Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
Office: (401) 762-0045
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.
While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.
The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.
Find us on Google Maps http://www.facebook.com/MCET.OB
Management and Board of Directors
Barbara (Corbett) Newmin - Investor Relations
P. (401) 762-0045
W. Gerald Newmin, Chairman and Chief Executive Officer
P. (941) 637-9883
Mr. W. Gerald Newmin joined the Company in June 1995. Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company. Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company. Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies. Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company. Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured. Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive. Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets. Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States. Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003. Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.
Dr. Steve Chang Ph. D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004. Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008. Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006. Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005. Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004. Dr. Chang has also held senior management positions at Chiron and Viagene. Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications. Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine. Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.
Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003. Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy). Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and held one or more of these positions until his retirement in 1998. Mr. Page joined SDG&E in 1978 as executive vice president and COO. In 1981, he was elected president and CEO and added the chairmanship in 1983. Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research. He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures. Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University. Mr. Page has been licensed as an engineer and as a certified public accountant (CPA). Mr. Page also serves on the University of California Presidents Council on the National Laboratories.
Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000. Mr. Sigmond has been in sales, marketing and operations management for the past 20 years. Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997. Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved. Mr. Sigmond studied Marketing and Chemistry at Duquesne University.
Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College. He is also the Principal of a healthcare and neuroscience consulting firm. From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies. Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution. At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994. Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region. Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology. Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology. Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio. Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.